Is axitinib/axitinib included in medical insurance?

Axitinib/Axitinib is an oral tyrosine kinase inhibitor mainly used to treat advanced renal cell carcinoma (RCC). Advanced renal cell carcinoma is a malignant tumor of the kidney that is usually diagnosed at an advanced stage and is difficult to treat. By inhibiting multiple growth factor receptors (such as VEGFR-1, VEGFR-2, VEGFR-3, etc.) related to tumor growth and angiogenesis, axitinib can effectively prevent the proliferation of cancer cells and the formation of new blood vessels required, thereby achieving the effect of inhibiting tumor growth. This drug is suitable for patients with advanced renal cell carcinoma who have not received systemic treatment, and can also be used for patients whose cancer has not improved after other systemic treatments. It is one of the important options for the treatment of renal cancer today.

In China, axitinib was approved by the State Food and Drug Administration in 2015 and has become one of the first- or second-line options for the treatment of advanced renal cell carcinoma. With the country's emphasis on cancer treatment drugs and the improvement of medical insurance policies, axitinib has gradually been included in the scope of medical insurance payment. This means that eligible patients can enjoy reimbursement from medical insurance and reduce their financial burden when treated with axitinib. This undoubtedly brings hope to the majority of cancer patients, allowing more patients to obtain effective treatment.

It should be noted that although axitinib has been included in medical insurance, specific reimbursement policies and conditions may vary by region. The medical insurance catalogs and reimbursement ratios may differ in different provinces and cities, so patients should consult the local medical insurance department or the pharmacy department of the hospital to understand the latest medical insurance policies and reimbursement procedures before use. In addition, when using axitinib, patients need to undergo standardized treatment under the guidance of a doctor, and regularly monitor the efficacy and adverse reactions so that the medication regimen can be adjusted in a timely manner.

Reference materials:https://www.inlyta.com/